title: A phase II study of hyperfractionated accelerated radiotherapy (HART) after induction cisplatin (CDDP) and vinorelbine (VNR) for stage III non-small-cell lung cancer (NSCLC).
abstract: OBJECTIVE
  The purpose was to assess the feasibility and efficacy of hyperfractionated accelerated radiotherapy (HART) after induction chemotherapy for Stage III non-small-cell lung cancer.
  
  
  METHODS
  Treatment consisted of 2 cycles of cisplatin 80 mg/m(2) on Day 1 and vinorelbine 25 mg/m(2) on Days 1 and 8 every 3 weeks followed by HART, 3 times a day (1.5, 1.8, 1.5 Gy, 4-h interval) for a total dose of 57.6 Gy.
  
  
  RESULTS
  Thirty patients were eligible. Their median age was 64 years (range, 46-73 years), 24 were male, 6 were female, 8 had performance status (PS) 0, 22 had PS 1, 9 had Stage IIIA, and 21 had Stage IIIB. All but 1 patient completed the treatment. Common grade > or =3 toxicities during the treatment included neutropenia, 25; infection, 5; esophagitis, 5; and radiation pneumonitis, 3. The overall response rate was 83%. The median survival was 24 months (95% confidence interval [CI], 13-34 months), and the 2-year overall survival was 50% (95% CI, 32-68%). The median progression-free survival was 10 months (95% CI, 8-20 months).
  
  
  CONCLUSIONS
  Hyperfractionated accelerated radiotherapy after induction of cisplatin and vinorelbine was feasible and promising. Future investigation employing dose-intensified radiotherapy in combination with chemotherapy is needed.
authors.affiliation: Division of Radiation Oncology, National Cancer Center Hospital East, 6-5-1 Kashiwa-noha, Kashiwa 277-8577, Japan. sishikur@east.ncc.go.jp
authors.forename: Satoshi
authors.initials: S
authors.lastname: Ishikura
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Ohe
authors.forename: Keiji
authors.initials: K
authors.lastname: Nihei
authors.forename: Kaoru
authors.initials: K
authors.lastname: Kubota
authors.forename: Ryutaro
authors.initials: R
authors.lastname: Kakinuma
authors.forename: Hironobu
authors.initials: H
authors.lastname: Ohmatsu
authors.forename: Koichi
authors.initials: K
authors.lastname: Goto
authors.forename: Seiji
authors.initials: S
authors.lastname: Niho
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Nishiwaki
authors.forename: Takashi
authors.initials: T
authors.lastname: Ogino
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D019583:Dose Fractionation, Radiation; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D017564:Radiation Pneumonitis / Q000209:etiology; D011879:Radiotherapy Dosage; D012074:Remission Induction; D017211:Treatment Failure; D014747:Vinblastine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D014747:Vinblastine; D002945:Cisplatin; D000077235:Vinorelbine